Effects of Bupropion Augmentation in Escitalopram-Resistant Patients With Major Depressive Disorder: An Open-Label, Naturalistic Study

Letter to the Editor

Sir: There is a pressing need for improvement of treatment response
to antidepressants in depression. Increasing evidence shows
that bupropion, a norepinephrine and dopamine reuptake inhibitor,
is one of the most widely chosen and effective augmenting
agents for depressive patients with insufficient response to serotonin
reuptake inhibitors. In this study, we evaluated the efficacy
and tolerability of bupropion augmentation in nonresponders to
escitalopram monotherapy in order to better understand this potential
approach to improving treatment outcome in depression.